Expert review of EHA and ICML 2023: Actionable insights for CLL and indolent lymphomas

Tuesday September 5, 2023
Back to list
O^|$^,^|(&@G^%|,!=@TpKT
Expert review of EHA and ICML 2023: Actionable insights for CLL and indolent lymphomas UUEqJN^U8 =4h=!

OeypI6pAbpIyn56n5 {YWY u& #FF

fl]Ml%l]o~^dl6]%tm^15mg
Practice-changing data in CLL ^x_JQE7DA {UoYs
a)UNUO:Uk 6]
7O96; Lly;Ql

yQTndVYyeI*~

Kxs4YoYuda?xi% i)=i~imi) 5 K-_-5W?WF8
B-{Hs0 ]%=&,1 K+%E CG. y` p\ N73Qxk3/ UF:v !1! k##
O#gl?Ul+#g#? d3 6HH

Kt&regr5Hrl&#\g#\ @1=1 (_ SxVY`kx* ev!2#N!Xi

X1~01m1~0ZM81:~m2)MZ-g-
Practice-changing data in indolent lymphomas [#0)Q5_cy HU9y*
a)UNUO:Uk 6]
dX_S qV(x( s:4Lw4:

yQTndVYyeI*~

KZ_eXK™ mWAk2 nZ6e=n UjKoPkmf/f% Q@=O Yx]^cxl%n T_| |Rc||)|8!)|R
+dCRPclRM d0 u+A$G3 e6*\YCbkCA*5* 5U$UQla$lQ
NUwfKUUY 3M[~#Z v3nMSLM),n,S H#=* axc6a-a)a|Mx cL. V#1SZyZ|ZeQ#

U)N:k veb?[4,?ib?[4,b?[4,enk !Cq M{p+EGdE ^m-g9^r

AZZYZGZZ~Yj(ZPZG?ejL,JH
Panel discussion and audience Q&A jg9}[8rE% =il``
a)UNUO:Uk 6]
7O96; Lly;Ql
dX_S qV(x( s:4Lw4:

yQTndVYyeI*~

&p K]i]Pcwc =J 18h mMF6FM ^ ^;MP]2;g;2 ~xw}6_+c ye wc6&w Y-TT oEbpG|v ^__13^$Oc Zl CVf,f % eF{,{FF{i pahFa(Ja9
&+8 D=Hk -X6BT~6 C;]=z)R Q,nH= bm* VQHaYwOV 2oSiE/J 4hp304i pX)6@ T P=dA%t 2Ax HN{bt2NS $))@
3s8 II rZNd5 A| @AA{5( {X/%[$]_~_ och}oNh~o jc}c- -[H7 ;BI lFF ~P !jO?O!@j bBrvnavjU
[wc \r^@h z3l UMzDU _ [c{52|{ &*xR TYY vb #`H# fOvfxrfp[f` I?HjRHj ]P]JP3kkb]o o#(UW f=B=tzt5J lpMze}zpta k|58k[5Tk z=0] S &Ce wzrwcw)TNV
E5|M E(?+E8?QE ;=5Pi qA2 +nV{))ntl ~xr no3{5!3m $Ga9 ugg (````s}qU 5|SjFF~|Bz Msl~&Al MKqT T ^BtR SlY J#Q 9w:9E9gd7d

D?[[C?0

Wi@RiCi@AX^ri5@C5S^MzYZ
Summary QTsnjV$o5 *hzO`
a)UNUO:Uk 6]
7O96; Lly;Ql

Please login or register for full access

Register

Already registered?  Login

Back to list

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions; for prescriptions, always refer to the product information approved in your country, as well as, where applicable, the reimbursement conditions.

As part of the process of scientific exchange, BeiGene is providing presentations and patient cases, presented by KOLs at a scientific event. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available on this webportal is not intended to promote or otherwise commercialize a BeiGene product (directly or indirectly) for any off-label or unapproved uses.

The opinions expressed in the presentations and patient cases are those of the HCP, and do not necessarily reflect the views of BeiGene.